Sphingosine kinase type 1 inhibitors and uses thereof
US-10456370-B2 · Oct 29, 2019 · US
Sphingosine kinase type 1 inhibitors and uses thereof
US10945971B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10945971-B2 |
| Application number | US-202016813961-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 10, 2020 |
| Priority date | Apr 29, 2008 |
| Publication date | Mar 16, 2021 |
| Grant date | Mar 16, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating myocardial infarction in a patient, comprising: administering to a patient in need of treatment for myocardial infarction a compound having the formula 2. The method of claim 1 , wherein the administering step comprises administering to the patient. 3. The method of claim 2 , wherein administering to the patient comprises administering to the patient. 4. A method for treating myocardial infarction in a patient, comprising: administering to a patient in need of treatment for myocardial infarction a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 5. The method of claim 4 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 6. The method of claim 5 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. 7. The method of claim 6 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. 8. The method of claim 7 , wherein R is a straight carbon chain or a branched carbon chain. 9. The method of claim 8 , wherein R is a straight carbon chain. 10. A method for treating myocardial infarction in a patient, consisting essentially of: administering to the patient. 11. A method for treating stroke in a patient, comprising: administering to a patient in need of treatment for stroke a compound having the formula 12. The method of claim 11 , wherein the administering step comprises administering to the patient. 13. The method of claim 12 , wherein administering to the patient comprises administering to the patient. 14. A method for treating stroke in a patient, comprising: administering to a patient in need of treatment for stroke a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 15. The method of claim 14 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 16. The method of claim 15 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. 17. The method of claim 16 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. 18. The method of claim 17 , wherein R is a straight carbon chain or a branched carbon chain. 19. The method of claim 18 , wherein R is a straight carbon chain. 20. A method for treating stroke in a patient, consisting essentially of: administering to the patient.
Assignees
Inventors
Classifications
Centrally acting analgesics, e.g. opioids · CPC title
Antiasthmatics · CPC title
with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms · CPC title
- A61K31/135Primary
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10945971B2 cover?
- Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.
- Who is the assignee on this patent?
- Enzo Therapeutics Inc, Univ Virginia Commonwealth
- What technology area does this patent fall under?
- Primary CPC classification A61K31/135. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).